Dual HER2 Blockade Promising in HER2-Positive Metastatic CRC

Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.

Source: CancerNetwork - April 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/AACR 2017 Colorectal Cancer Gastrointestinal Cancer News Source Type: news